Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | NMT1 | P30419 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15796727 | 0.84 | COMT (0.42) | COMTNPC1GAAMAPK1RAB9A | |
| SCHEMBL7613775 | 0.83 | CYP1A2 (0.33) | COMTGAACYP1A2HRH2HRH1 | |
| SCHEMBL260055 | 0.83 | CYP1A2 (0.37) | COMTNPC1GAAMAPK1RAB9A | |
| Bromide SCHEMBL5591179 | 0.82 | CYP1A2 (0.36) | COMTNPC1GAAMAPK1RAB9A | |
| SCHEMBL14329776 | 0.78 | NPC1 (0.42) | NPC1GAAMAPK1RAB9AFBP1 | |
| SCHEMBL9950551 | 0.78 | COMT (0.39) | COMTNPC1GAAMAPK1RAB9A | |
| SCHEMBL3274275 | 0.78 | POLB (0.37) | — | |
| SCHEMBL13301451 | 0.76 | MEN1 (0.41) | COMTGAACYP1A2 | |
| SCHEMBL27748701 | 0.75 | — | — | |
| SCHEMBL95057 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189839-B2 | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase | ACTELION PHARMACEUTICALS LTD (CH) | 2019-01-29 | — | — | US | disclosed |
| EP-3071578-B1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-01-10 | — | — | EP | disclosed |
| US-9765092-B2 | Tricyclic piperidine compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2017-09-19 | — | — | US | disclosed |
| EP-3071567-B1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | ACTELION PHARMACEUTICALS LTD (CH) | 2017-09-06 | — | — | EP | disclosed |
| EP-2838891-B1 | AROMATIC RING COMPOUND AS GHRELIN O-ACYLTRANSFERASE INHIBITOR | TAKEDA PHARMACEUTICALS CO (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-20160289232-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | ACTELION PHARMACEUTICALS LTD (CH) | 2016-10-06 | — | — | US | disclosed |
| EP-3071578-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | Actelion Pharmaceuticals Ltd (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-3071567-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | Actelion Pharmaceuticals Ltd (CH) | 2016-09-28 | — | — | EP | disclosed |
| US-20160272655-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-09-22 | — | — | US | disclosed |
| US-9238639-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-19 | — | — | US | disclosed |
| CN-102050758-A | Novel amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORP | 2011-05-11 | — | — | CN | disclosed |
| US-7855297-B2 | Amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20100041656-A1 | Novel amide derivatives and medicinal use thereof | NAKAMURA MITSUBARU | 2010-02-18 | — | — | US | disclosed |
| US-20040138223-A1 | Novel amide derivatives and medicinal use thereof ugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-15 | — | — | US | disclosed |
| CN-1474803-A | Novel amide derivative and medical use thereof | ������ҩ��ʽ���� | 2004-02-11 | — | — | CN | disclosed |
| EP-1318140-A1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF UGS | Mitsubishi Pharma Corporation (JP) | 2003-06-11 | — | — | EP | disclosed |
| US-6515124-B2 | (Z)-2-((2-bromo-4-(((3-hydroxybenzyl)amino)carbonyl)benzoyl) -amino)pent-2-enoic acid, for example; useful for treating psoriasis | HOFFMAN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1261579-A1 | DEHYDROAMINO ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-20020161237-A1 | Dehydroamino acids | HOFFMANN-LA ROCHE INC. | 2002-10-31 | — | — | US | disclosed |
| WO-2001058853-A1 | DEHYDROAMINO ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161237-A1 | Dehydroamino acids | HSD3B1, CYP8B1, TH | COMT 2959/4885NPC1 3708/4885GAA 4521/4885 |
| US-10189839-B2 | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase | TPH1, TPH2, MAOB | COMT 74/4885NPC1 2247/4885GAA 1316/4885 |
| US-20160272655-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | TPH1, HTR1B, HTR1A | COMT 460/4885NPC1 1088/4885GAA 2588/4885 |
| US-20100041656-A1 | Novel amide derivatives and medicinal use thereof | C5AR1, C5AR2, C3AR1 | COMT 2775/4885NPC1 3015/4885GAA 3289/4885 |
| US-20160289232-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | TPH1, TPH2, MAOB | COMT 74/4885NPC1 2247/4885GAA 1316/4885 |
| US-20040138223-A1 | Novel amide derivatives and medicinal use thereof ugs | C5AR1, C5AR2, C1S | COMT 3495/4885NPC1 2771/4885GAA 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.